Anti-Neuroinflammatory Cannabinoid Acids as a New Therapeutic Approach for Multiple Sclerosis
Abstract Neuroinflammation is a hallmark of multiple sclerosis (MS). MS is marked by glial cell activation, autoreactive T cells, and…
Abstract Neuroinflammation is a hallmark of multiple sclerosis (MS). MS is marked by glial cell activation, autoreactive T cells, and…
Abstract Insomnia is increasingly recognized as a manifestation of multisystem dysregulation characterized by sustained physiological hyperarousal. This review situates insomnia…
Abstract Drug-resistant epilepsy (DRE) affects approximately 30% of individuals with epilepsy and remains a major clinical challenge despite the availability…
Abstract Background: Methamphetamine (MA) use in people living with HIV (PLWH) has been linked to neurocognitive and behavioral dysregulation. We…
Abstract Regulated cell death (RCD) is well-known as a controlled form of cell death regulated by one or more cascading…
Abstract Epilepsy is a common neurological disorder associated with recurring seizures that in about one-third of individuals are resistant to…
Abstract Background: Alzheimer’s disease (AD) remains the most prevalent cause of dementia, yet no existing treatment effectively prevents its onset.…
Abstract Background: Transient receptor potential (TRP) ion channels, a ubiquitous family of nonselective cation channels, are extensively expressed across the…
Abstract Alzheimer’s disease (AD) is a pervasive neurodegenerative disorder characterized by chronic neuroinflammation; current interventions primarily offer symptomatic relief. Cannabidiol…
Abstract Supplementary Information: The online version contains supplementary material available at 10.1007/s12035-025-05608-8. Article type: Research Article Keywords: Cannabidiol, Schizophrenia therapy,…